GlassScriptPhysician profile
William W Cook
NPI 1831155456
$6,613.06
in general payments reported to CMS, 2019-2025
34 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,351 · 2020: $2,340 · 2021: $421 · 2022: $311 · 2023: $20.24 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,146.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,079.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $740.08 | 2019-2022 | |
| Genentech USA, INC. | $495.26 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $475.98 | 2019-2020 | |
| Grifols USA, LLC | $409.44 | 2019-2022 | |
| Philips North America LLC | $241.68 | 2019-2020 | |
| Mylan Specialty L.P. | $224.74 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $185.28 | 2019 | |
| Shire North American Group INC | $181.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $168.45 | 2019-2022 | |
| Circassia INC. | $126.84 | 2019-2020 | |
| Insmed, INC. | $118.46 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.59 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $98.83 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.36 | 2019-2020 | |
| Advanced Respiratory, INC | $84.05 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $78.47 | 2019 | |
| Gilead Sciences, INC. | $68.72 | 2021-2022 | |
| Pfizer INC. | $47.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $45.48 | 2020 | |
| Electromed, INC. | $44.54 | 2019 | |
| Genzyme Corporation | $41.30 | 2019 | |
| Amgen INC. | $40.68 | 2022 | |
| Alexion Pharmaceuticals, INC. | $39.07 | 2020 | |
| Sanofi-Aventis U.S. LLC | $38.78 | 2020 | |
| Baxter Healthcare | $36.24 | 2022 | |
| Astellas Pharma US INC | $33.67 | 2020 | |
| Optinose US, INC. | $28.88 | 2019 | |
| Novo Nordisk INC | $25.29 | 2019 | |
| Urogen Pharma, INC. | $20.24 | 2023 | Jelmyto |
| Jazz Pharmaceuticals INC. | $20.14 | 2020 | |
| United Therapeutics Corporation | $17.72 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.